Indivior Pharmaceuticals, Inc 6-K, filed Mar 21, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-03-21
For: 2024-03-21
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on March 21, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: March 21, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: March 21, 2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the
relevant issuer and to the FCA in Microsoft Word format
if possible) i
|
||||||
|
|
||||||
|
1a. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attached ii:
|
Indivior
PLC
|
|||||
|
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X"
if appropriate)
|
||||||
|
Non-UK issuer
|
|
|||||
|
2. Reason for the notification (please mark the
appropriate box or boxes with an "X")
|
||||||
|
An
acquisition or disposal of voting rights
|
X
|
|||||
|
An
acquisition or disposal of financial instruments
|
|
|||||
|
An
event changing the breakdown of voting rights
|
|
|||||
|
Other
(please specify) iii:
|
|
|||||
|
3. Details of person subject to the notification
obligation iv
|
||||||
|
Name
|
Scopia
Capital Management LP
Scopia
Management, Inc.
|
|||||
|
City
and country of registered office (if applicable)
|
Wilmington,
Delaware, United States (ScopiaCapital Management LP)
New
York, New York, United States (ScopiaManagement, Inc.)
|
|||||
|
4. Full name of shareholder(s) (if different from
3.) v
|
||||||
|
Name
|
Goldman
Sachs & Co.
Morgan
Stanley & Co., LLC
|
|||||
|
City
and country of registered office (if applicable)
|
New
York, New York, United States
|
|||||
|
5. Date on which the threshold was crossed or
reached vi:
|
19
March 2024
|
|||||
|
6. Date on which issuer notified
(DD/MM/YYYY):
|
21
March 2024
|
|||||
|
7. Total positions of person(s) subject to the notification
obligation
|
||||||
|
|
% of
voting rights attached to shares (total of 8. A)
|
% of voting rights through financial instruments(total of 8.B 1 + 8.B
2)
|
Total
of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer (8.A +
8.B) vii
|
||
|
Resulting
situation on the date on which threshold was crossed or
reached
|
4.62%
|
0.09%
|
4.71%
|
6,412,546
|
||
|
Position
of previous notification (if
applicable)
|
6.96%
|
Not
Applicable
|
6.96%
|
|
||
|
|
|
|
|
|
|
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached viii
|
|||||||||
|
A: Voting rights attached to shares
|
|||||||||
|
Class/type ofshares
ISIN
code (if possible)
|
Number of voting rights ix
|
% of voting rights
|
|||||||
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
||||||
|
GB00BN4HT335
|
|
6,289,509
|
|
4.62%
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
SUBTOTAL 8. A
|
6,289,509
|
4.62%
|
|||||||
|
|
|||||||||
|
B 1: Financial Instruments according to DTR5.3.1R (1)
(a)
|
|||||||||
|
Type of financial instrument
|
Expiration date x
|
Exercise/Conversion Period xi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of voting rights
|
|||||
|
Swap
|
07
August 2025
|
Swap
may be terminated at any time up to Expiration Date
|
123,037
|
0.09%
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
SUBTOTAL 8. B 1
|
123,037
|
0.09%
|
|||||
|
|
|||||||||
|
B 2: Financial Instruments with similar economic effect according
to DTR5.3.1R (1) (b)
|
|||||||||
|
Type of financial instrument
|
Expiration date x
|
Exercise/Conversion Period xi
|
Physical or cash
Settlement xii
|
Number of voting rights
|
% of voting rights
|
||||
|
Not
Applicable
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
||||
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
||||
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
9. Information in relation to the person subject to the
notification obligation (please mark
the
applicable
box with an "X")
|
||||
|
Person subject to the notification obligation is not controlled by
any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer xiii
|
|
|||
|
Full chain of controlled undertakings through which
the voting rights and/or thefinancial instruments are effectively
held starting with the ultimate controlling natural person or legal
entity (please add additional rows as
necessary) xiv
|
X
|
|||
|
Name xv
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
Scopia
Management, Inc.
|
4.62%
|
0.09%
|
4.71%
|
|
|
Scopia
CapitalManagement LP
|
4.62%
|
0.09%
|
4.71%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
10. In case of proxy voting, please
identify:
|
||||
|
Name of
the proxy holder
|
|
|||
|
The
number and % of voting rights held
|
|
|||
|
The
date until which the voting rights will be held
|
|
|||
|
|
||||
|
11. Additional information xvi
|
||||
|
|
||||
|
|
|
|
|
|
|
Place of completion
|
New
York, NY, United States
|
|
Date of completion
|
21
March 2024
|